Clinical Test Results Shows GeneLink's Dermagenetics™ Skin-Care Formula Reverses Signs of Aging
June 2, 2004

MARGATE, NJ – BUSINESS WIRE – June 2, 2004 – GeneLink BioSciences, Inc. (OTCBB:GNLK) the bioscience company announced today that a recent clinical trial showed that its Dermagenetics™ skin-care formulation significantly reduced the signs of skin wrinkling and skin-aging while outperforming a similar placebo crème.

The eight week, double-blind, randomized and controlled study compared the performance of placebo crème versus the performance of a "genetically guided" crème containing active ingredients formulated for each participant. Utilizing GeneLink's patent pending Dermagenetics™ Profile Assessment, thirty-one women were genetically pre-screened and provided with individualized formulations linked to their genetic predispositions

For those using the genetically guided formulations, 62% reported substantial reduction in the appearance of wrinkles after 14 days of treatment. After 56 days, the number of participants reporting reduction in the appearance of wrinkles rose to 70%. Similarly, after 14 days, 56% of the participants indicated improved skin-firmness and after eight weeks of treatment those with improvements in skin-firmness rose to 70%.

The final report is still being drafted but will include physiological measurements in skin firmness, wrinkle reduction, skin moisture, skin tone, skin suppleness, and skin pigment uniformity.

"GeneLink is the first and only company to offer a 'personalized skin-care system' utilizing the power of SNP (single nucleotide polymorphism) based genetic information," says John DePhillipo, GeneLink's CEO. "GeneLink is now in a position to license these powerful new anti-aging skin care products to both national and international companies with well established distribution bases."

GeneLink's formulations address key individual genetic characteristics that can accelerate skin aging, skin wrinkling and other specific oxidative stress deficiencies in the skin and preliminary studies demonstrate that GeneLink's system is significantly more effective than random topical anti-aging skin products. The "genetically guided" skin-care system is exclusively offered in combination with GeneLink's Dermagenetics™ Profile Assessment which predicts a person's resistance to skin aging, skin irritation and tissue breakdown.

About GeneLink
GeneLink BioSciences, Inc., since 1994, created the World's First Family Centered DNA Bank and Hereditary Genetic Information Service. The Genetic Biosciences company is a pioneer and leading provider of DNA tests created to facilitate "genetically guided" health, beauty and wellness products. The company both markets and licenses the GeneLink Nutragenetic Profile™ and its Dermagenetics™ test to the $1.4 trillion cosmetics, nutritional supplement and healthcare industries. For more information about GeneLink, visit its web site at www.genelink.info.

This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.